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The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24h-
continuous infusion of 5-flourouracil (FU) plus folinic acid, and to assess the toxicity and activity in patients with previously treated
colorectal and gastric cancer. Escalating doses of MMC starting from 6mgm
 2 in 2mgm
 2-steps to a maximum of 10mgm
 2 were
applied on days 1 and 22, given to fixed doses of 5-FU (2.600mgm
 2) as 24h infusion and folinic acid 500mgm
 2 prior to 5-FU
weekly for 6 weeks. At least three patients were treated at each dose level. A total of 16 patients have been included in the phase I
study. At the highest dose level (MMC 10mgm
 2), grade III thrombocytopenia, dyspnoea, mucositis and diarrhoea were observed in
one patient each (17 %). In the phase II study 45 patients, 33 with colorectal cancer and 12 with gastric cancer, 23 patients after failure
of first- and 22 patients after at least second-line or subsequent chemotherapy have been treated. Seven partial responses (PR) were
registered (16%), one (3%; CI95%, 0–16) in colorectal and six (50%; CI95%, 21–79%) in gastric cancer patients. In all, 17 (38%)
achieved disease stabilisation, 15 colorectal (45%, CI95%, 28–64%) and two gastric cancer patients (17%; CI95%, 2–48%). The median
progression-free survival was 3.1 months (range, 0.9–9.1) in colorectal and 4.6 months (range, 0.7–12.4) in gastric cancer. The
median overall survival time was 6.6 months (range, 1.9–15.6) in colorectal and 7.1 months (range, 1.7–20.8) in patients with gastric
cancer. This regimen was considered to be safe and well tolerated for pretreated patients with gastrointestinal adenocarcinoma. In
gastric cancer,MMC plus infusional 5-FU/folinic acid may be a potential second-line regimen with promising antitumour activity.
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Mitomycin C (MMC) is a quinone-containing antitumour anti-
biotic that is reductively activated by a variety of enzymatic
systems to metabolites that alkylate and crosslink DNA (Dorr,
1988). The treatment with MMC results in the formation of
reactive oxygen species, which also contribute to its cytotoxicity
(Doroshow, 1986; Pritsos and Sartorelli 1986; Dusre et al, 1990).
Intracellular glutathione (GSH) participates in the detoxification of
alkylating agents by converting reactive intermediates into
noncytotoxic metabolites, and cells with increased pools of GSH
have been shown to develop resistance to MMC (Dorr, 1988).
Single-agent MMC reaches remission rates of approximately
10–20% in patients with advanced gastrointestinal cancer, in first-
line as well as in second-line therapy (Moertel et al, 1968; Moertel,
1975). In patients refractory to 5-flourouracil (FU) /folinic acid,
first-line chemotherapy single-agent MMC has shown antitumour
efficacy (Hartmann et al, 1998a; Hartmann et al, 1999). Partial
remissions have been found particularly in gastric cancer, as well
as disease stabilisations in colorectal cancer patients. When
combined with continuous infusional 5-FU/folinic acid, an
increased antitumour activity was found in pretreated gastro-
intestinal adenocarcinomas with objective remission rates of about
10% in colorectal and up to 46% in gastric cancer patients (Chester
et al, 2000; Kretzschmar et al, 2000; Hofheinz et al, 2002). Different
schedules and dosages of MMC have been used in previous trials
(Ross et al, 1997; Kretzschmar et al, 2000; Chang et al, 2002;
Hofheinz et al, 2002; Tebbutt et al, 2002), but no systematic
investigation to determine the maximum tolerated dose (MTD) of
MMC when combined with 5-FU/folinic acid has been performed
so far.
The aim of this nonrandomised multicentre phase I/II study was
first to define the MTD of bolus MMC in combination with
continuous infusional 5-FU plus high-dose folinic acid. In the
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adding MMC to 5-FU/folinic acid in 5-FU-resistant patients with
metastatic gastrointestinal adenocarcinomas.
PATIENTS AND METHODS
Eligibility
Patients eligible for this study had advanced disease of a
histologically confirmed gastrointestinal adenocarcinoma. In the
phase I part of this study, patients were allowed to be pretreated
with any palliative chemotherapy. Objective evidence of tumour
progression must have occurred while the patient was receiving
chemotherapy or within 6 months from receiving the last dose of
prior chemotherapy. Disease must have been bidimensional
measurable in X-ray, ultrasound or computed tomography.
In the phase II part of the trial, patients were allowed to have up
to two prior 5-FU-based chemotherapy regimens, bolus and/or
continuous infusion of 5-fluorouracil/folinic acid. Adjuvant
chemotherapy was also permitted. Patients must have been
between 18 and 75 years, have a performance status of 0–2
according to the ECOG criteria and a life expectancy of at least 3
months. Other inclusion criteria consisted of pretreatment
neutrophile count X2000ml
 1, platelet count X150000ml
 1,
serum creatinine concentration p2.0mgdl
 1 and total bilirubin
levels p2.0mgdl
 1. Exclusion criteria were known incompatibility
to 5-FU or MMC, the presence of central nervous metastases,
serious or uncontrolled concurrent medical illness or secondary
malignancies except for basal cell carcinoma of the skin or
carcinoma in situ of cervix uteri. All patients were informed of the
investigational nature of this study and had to provide written
informed consent in accordance with institutional and federal
guidelines. The multicentre study was reviewed and approved by
the local ethical committee of all participating centres. Treatment
was performed according to the Declaration of Helsinki.
Treatment protocol
Chemotherapy consisted of 7-weekly courses of 2600mgm
 2 5-FU
i.v. as a 24-h continuous infusion combined with 500mgm
 2
folinic acid i.v. applied over 2h or simultaneously in one infusion
bag as a 24-h infusion with 5-FU (Oncolfolic
s, Medac, Hamburg,
FRG), both given weekly for 6 weeks followed by 1 week rest. The
treatment was restarted on day 50. Mitomycin C was administrated
as bolus injection in three dose escalation steps of 6, 8 and
10mgm
 2 on days 1 and 22. At least three patients were treated at
each dose level in the first part (phase I). Treatment was continued
for at least two treatment cycles. Escalation proceeded to dose level
3 unless two out of three or four out of six patients experienced a
dose-limiting toxicity (DLT) after the first cycle. Treatment was
applied in an outpatient oncology setting. All patients prophy-
lactically received 50mg of prednisolone i.v. before mitomycin
application. Antiemetic premedication was left up to the decision
of the treating physician. Most patients received 5-HT3-antagonists
or metoclopramide prior to treatment.
Evaluation of response and toxicity
All patients were assessed prior to treatment by physical
examination, routine haematology and biochemistry analysis,
chest X-ray and CT scan to define the extent of disease. Complete
blood cell counts with platelets and differential counts were
obtained weekly during chemotherapy, and serum chemistry
analyses were repeated at least once every course. Subjective
symptoms, physical examination, performance status and all
adverse reactions were recorded before each treatment cycle.
Tumour size was measured every cycle by CT scan, X-ray or any
other technique that allows retrospective and independent
assessment.
Determination of tumour response followed WHO standard
criteria: complete remission (CR) was defined as a complete
disappearance of all evidence of disease. A partial response (PR)
was defined as radiological response 450% in tumour size, and
response o50% or progression o25% was defined as stable
disease. Progressive disease was defined as either residual lesions
increasing in size or occurrence of new lesions.
Treatment was continued until one of the following criteria was
met: development of progressive disease or of unacceptable
toxicity; intercurrent, noncancer-related illness that prevented
continuation of therapy or regular follow-up evaluation; with-
drawal of consent. The duration of response was defined as the
interval from the onset of response until evidence of disease
progression. Overall survival was defined as the interval from the
date of study until death (or last contact if the patient was still
alive).
Dose-limiting toxicity was defined as grade IV haematological
toxicity (neutrophile granulocyte, thrombocytes), diarrhoea grade
III, febrile neutropenia grade III with any grade of diarrhoea or any
organ toxicity grade III (nephrotoxicity grade II), except alopecia
and nausea. Dose modifications for the following treatment cycles
were based on the worst toxicity observed during the previous
cycle of chemotherapy. Treatment was delayed in case of
leucocytes o3000ml
 1 or thrombocytes o75000ml
 1 to a max-
imum length of 2 weeks.
Statistical analysis
All information was included into a database at Tuebingen
University Medical Center, Germany. Statistical analyses were
performed using the SPSS system (SPSS for windows 10.0 software,
Microsoft Corp., Redmond, WA, USA). Exact 95% confidence
intervals (CI) around the observed response rate were calculated
from the binominal distribution. The Kaplan–Meier method was
used to determine overall and progression-free survival distribu-
tions. The overall survival calculation used death due to any reason
as the endpoint (Kaplan and Maier, 1958).
RESULTS
Between September 1999 and May 2002, a total of 61 patients with
advanced gastrointestinal cancer failing 5-FU-based chemotherapy
were included according to the study protocol.
Phase I
A total of 16 patients were entered into the phase I part and all
three planned consecutive dose levels, including 6, 8 and
10mgm
 2 of bolus MMC, have been tested. At the highest dose
level (10mgm
 2 mitomycin) grade III thrombocytopenia, dys-
pnoea, mucositis and diarrhoea were observed in one patient each
(17%). No grade IV toxicity was seen in this phase I part of the
study and no grade III toxicity occurred at the dose levels of 6 or
8mgm
 2 MMC. Therefore, 10mgm
 2 was considered to be the
MTD of mitomycin given on days 1 and 22 in combination with
weekly infusional 5-FU plus folinic acid. Toxicity according to
WHO criteria at dose level 3 during the phase I study is listed in
Table 1.
Phase II
Patients’ characteristics In total, 45 patients, 37 men and 8
women, were entered into the phase II study. All were assessable
for response evaluation, survival analysis and toxicity. A summary
of baseline patients’ characteristics is given in Table 2.
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lIn all, 11 patients (24%) had colon, 22 (49%) rectal and 12 (27%)
had gastric adenocarcinomas. The majority of patients were
symptomatic, with 27 patients (60%) having an ECOG-perfor-
mance status of 1 and six patients (13%) of 2. A total of 23 patients
(51%) were included after failure of first- and 22 patients (49%)
after at least one further line of chemotherapy. In all, 50% of the
patients (n¼6) with gastric cancer had been pretreated with
continuous infusional 5-FU as prior treatment and 33% of the
patients (n¼4) had received 5-FU-combination chemotherapy
with cisplatin. In patients with colorectal cancer, previous
chemotherapy consisted of bolus 5-FU in 27% (n¼9) and
continuous infusion of 5-FU in 46% (n¼15). A total of 27%
(n¼9) had received continuous 5-FU plus either irinotecan or
oxaliplatin.
Safety and toxicity assessment
A median number of two cycles of MMC and 5-FU/folinic acid
(range, 1–3) have been applied during the phase II trial. The
combination of continuous infusional 5-FU plus folinic acid and
bolus MMC was well tolerated. The side effects observed in the
phase II are listed in Table 3.
No renal dysfunction, pulmonary toxicity such as irreversible
interstitial pneumonia or evidence of haemolytic uraemic syn-
drome or haemolytic anaemia was observed. The most frequent
severe haematological toxicity (grade III/IV according to the WHO
criteria) during the phase II trial was thrombocytopenia in 16% of
the patients (n¼7). In three of those seven patients, thrombocy-
topenia occurred during the first cycle, and in the remaining four
patients in the second cycle. Treatment has to be delayed for 2
weeks in one single patient. One of seven patients had
thrombopenia grade II prior to the start of treatment with MMC/
5-FU due to pretreatment. Patients with severe thrombopenia
regenerated slowly after withdrawal of treatment. Mild thrombo-
cytopenia was more frequent (n¼17, 38%). Leucocytopenia grade
I/II occurred in 47% of the patients (n¼21), and grade III/IV was
seen in 7% of the patients (n¼3). In all, 4% of the patients (n¼2)
experienced severe neutropenic infections. Nonhaemolytic anae-
mia grade III occurred in 7% of the patients (n¼3). These patients
all had mild anaemia prior to the study. Diarrhoea was the most
frequent nonhaematologic grade III/IV toxicity in 16% of the
patients (n¼7), followed by nausea and emesis in 7% (n¼3). Mild
hand–foot syndrome was observed in 20% of the patients (n¼9).
No treatment-related death was seen and no catheter-related
complications were observed. The treatment dosage had to be
reduced in 11% of the patients (n¼5) due to toxicity. Treatment
was delayed for at least 1 week during the whole treatment in 20
patients (44%) due to toxicity. Seven patients (16%) were
hospitalised as a result of toxicity in seven of 85 cycles (8%).
Response evaluation
Seven patients (16%) attained an objective response to the
combination of infusional 5-FU plus folinic acid and MMC, one
of 33 patients with colorectal and six of 12 patients with gastric
carcinoma. This represents a 50% response rate (CI95% 21–79) for
the 12 patients with gastric adenocarcinoma, and a 3% response
rate (CI95% 0–16) in colorectal cancer patients. No complete
response was seen. Disease stabilisations were achieved in 17
patients (38%), 15 with colorectal cancer (45%, CI95% 28–64) and
Table 1 Toxicity at dose level 3 (10mgm
 2 MMC) according to the
WHO criteria in the phase I (n¼6 patients; n¼9 cycles)
Definition of toxicity Grade I/II (%) Grade III (%) Grade IV (%)
Neutropenia 2 (33 %) 0 0
Thrombocytopenia 2 (33 %) 1 (17%) 0
Anemia (nonhaemolytic) 2 (33%) 0 0
Nausea 1 (17%) 0 0
Emesis 1 (17%) 0 0
Diarrhoea 1 (17%) 1 (17%) 0
Constipation 2 (33%) 0 0
Dyspnoea 0 1 (17%) 0
Mucositis 1 (17%) 1 (17%) 0
Hand–foot syndrome 1 (17%) 0 0
Table 2 Characteristics of patients treated at dose level 3 (10mgm
 2
MMC) during the phase II study (n¼45 patients)
N (patients) %
Sex 37 82
Male
Female 8 18
Median age 59 years (range, 44–73)
Performance status (ECOG)
01 2 2 7
12 7 6 0
26 1 3
Site of primary tumour
Colon carcinoma 11 24
Rectal carcinoma 22 49
Gastric carcinoma 12 27
Sites of metastases
Liver 35 78
Lymph node 16 36
Lung 20 44
Locoregional recurrence 15 33
Bone 2 4
Other 7 16
No. of previous chemotherapy regimens
n¼12 3 5 1
nX22 2 4 9
Prior chemotherapeutic regimens
in gastric cancer (n¼12)
c.i. 5-FU 6 50
c.i. 5-FU combined with cisplatin 4 33
Other 2 22
First-line chemotherapeutic regimen
in colorectal cancer (n¼33)
Bolus 5-FU 9 27
c.i. 5-FU 15 46
c.i. 5-FU combined with irinotecan 3 9
c.i. 5-FU combined with oxaliplatin 6 18
c.i.¼continuous infusion.
Table 3 Worst toxicity per patient during treatment with 5-FU/folinic
acid and MMC in phase II (n¼45 patients; n¼85 cycles)
Definition of toxicity Grade I/II (%) Grade III (%) Grade IV (%)
Anaemia 25 (55 %) 3 (7 %) 0
Leucocytopenia 21 (47 %) 3 (7 % ) 0
Thrombocytopenia 17 (38 %) 7 (16 %) 0
Infection 3 (7 %) 2 (4 %) 0
Diarrhoea 15 (33 %) 7 (16 %) 0
Mucositis 11 (24 %) 2 (4 %) 0
Constipation 7 (16 %) 0 0
Emesis 22 (49 %) 3 (7 %) 0
Nausea 16 (36 %) 3 (7 %) 0
Hand–foot –syndrome 9 (20 %) 0 0
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ltwo with gastric cancer (17%, CI95% 2–48). In all, 17 patients with
colorectal cancer (52%, CI95% 33–69) and four patients with
gastric cancer (33%, CI95% 10–65) had progressive disease at the
first tumour evaluation on treatment with MMC/-5-FU.
The median progression-free survival was 3.1 months (range,
0.9–9.1) in patients with advanced colorectal cancer and 4.6
months (range, 0.7–12.4) in gastric cancer patients. The median
overall survival in patients with colorectal cancer was 6.6 months
(range, 1.9–15.6) and 7.1 months in patients with gastric cancer
(range, 1.7–20.8). Patients responding to treatment and those with
tumour stabilisation achieved a median survival of 9.5 months
(range, 3.8–20.8), whereas in patients with progressive disease the
median survival was 5.3 months (range, 1.7–12.4).
The 23 patients with one previous line of chemotherapy prior to
the start of 5-FU/folinic acid plus MMC had a median survival of
8.4 months (range, 1.6–18.3), and the 22 patients with at least two
previous chemotherapy regimen survived for only 5.9 months
(range, 1.3–15.6). Of the patients, 14 (61%) with second-line 5-FU/
folinic acid plus MMC treatment achieved at least disease
stabilisation and 10 patients (39%) had progressive disease,
while in patients X2 previous regimens, only 45% (n¼10)
responded to treatment and 55% (n¼12) had progressive
disease. Patients with gastric cancer developing progressive
disease while receiving previous chemotherapy had a lower
probability to attain an objective response compared to the
subgroup of patients with progressive or recurrent disease within 6
months of receiving the last dose of previous chemotherapy
(P¼0.02) (see Table 4).
DISCUSSION
The prognosis of patients with recurrent metastatic gastric cancer
is dismal, with a median survival ranging between 3 and 5 months
in untreated patients (Glimelius et al, 1997). In advanced gastric
cancer, first-line use of palliative combination chemotherapy
compared with best supportive care is superior in terms of quality
of life and overall survival. Whether this is also true for patients
with relapse after first-line chemotherapy is currently not proven.
Comparable to the treatment strategies in colorectal cancer, in
recent years, several attempts have been made to improve the
results by introducing continuous 5-FU infusion into polyche-
motherapy regimens in this disease. Mitomycin C is among the
most effective single agents for the treatment of advanced gastric
cancer (Schnall and Macdonald, 1993).
Although second-line chemotherapy in gastric cancer is not
considered as a standard approach, phase II data are available for
5-FU/folinic acid, docetaxel, fotemustine and paclitaxel, demon-
strating objective remission rates in a range of 0–22% and overall
survival times ranging from 3 to 8 months (Vanhoefer et al, 1994;
Di Bartolomeo et al, 1996; Rougier et al, 1996; Cascinu et al, 1998;
Wilke et al, 1998). By using continuous infusional MMC as a single
agent, 30% of pretreated gastric cancer patients will achieve an
objective remission. However, the median survival time is short
with approximately 3–4 months (Hartmann et al, 1998a;
Hartmann et al, 1999).
The cellular mechanism of the clinically observed synergy
between MMC and infusional 5-FU has not been further
elucidated, although time-dependent interactions between both
drugs on human cancer cell lines have been reported (Russello
et al, 1989). In previous trials, MMC was applied either using
absolute doses (e.g. 15mg; Chang et al, 2002) or in relation to body
surface with 7–10mgm
 2 on a 3-weekly basis. However, a
systematic investigation to determine the MTD of MMC when
combined with 5-FU/folinic acid has not been performed so far
(Ross et al, 1997; Kretzschmar et al, 2000; Hofheinz et al, 2002;
Tebbutt et al, 2002). With different schedules – one single
injection of 15mgm
 2 mitomycin on day 1 (Kretzschmar et al,
2000) or by combining infusional 5-FU with folinic acid with
10mgm
 2 MMC every 3, respectively every 6, weeks (Hofheinz
et al, 2002; Tebbutt et al, 2002) – survival in gastric cancer patients
ranging from 5.3 to 10.2 months has been reported. Objective
remission rates between 37 and 51% have been observed
(Kretzschmar et al, 2000; Hofheinz et al, 2002; Tebbutt et al,
2002). In the phase I part of the present study, the MTD of MMC
when combined to weekly infusional 5-FU plus folinic acid was
10mgm
 2 at days 1 and 22, and the rate of partial responses in the
phase II was 50% lasting for a median of 3.5 months in pretreated
gastric cancer patients. Furthermore, 31% of the patients achieved
disease stabilisation. The overall survival for these patients was 7.1
months; not significantly longer compared to investigations of
other agents as second-line treatment. This demonstrates the
aggressive biology of the disease with a short interval between
progression after chemotherapy and death.
Several trials have demonstrated that MMC also displays some
activity in previously treated patients with colorectal cancer
(Moertel et al, 1968; Conti et al, 1995; Hartmann et al, 1998a). A
recent phase III trial in advanced colorectal cancer comparing
protracted infusion of 5-FU with or without the addition of MMC
demonstrated an overall response rate of 45% for the combination
and 38% for 5-FU alone. The failure-free survival was 7.9 months
in favour of the combination compared to 5.4 months for 5-FU
alone. In addition, the global quality of life scores at 6 months was
better for 5-FU and MMC (Ross et al, 1997). In the second-line
setting, a considerable number of trials using MMC plus
continuous infusional 5-FU have been carried out demonstrating
that the addition of MMC to 5-FU can overcome resistance to first-
line chemotherapy in a distinct number of patients (Conti et al,
1995; Becker et al, 1997; Seitz et al, 1998; Chester et al, 2000;
Tassinari et al, 2000; Grumett et al, 2001; Ross et al, 2002).
In the present investigation, using MMC at maximum doses in
combination with infusional 5-FU, a low remission rate of 3% was
observed. However, 45% of patients revealed disease stabilisation
lasting for a median interval of 3.2 months. These data are clearly
inferior to other agents such as irinotecan (CPT-11) (Rothenberg
et al, 1996; Rougier et al, 1997; Van Cutsem et al, 1999) or
oxaliplatin plus 5-FU/folinic acid (de Gramont et al, 1997), and
appear equal to infusional 5-FU plus high-dose folinic acid
(Ardalan et al, 1991; Weh et al, 1994; Hartmann et al, 1998b)
alone. Thus, with currently available treatment options for
metastatic colorectal cancer, a clear role for infusional 5-FU/bolus
MMC cannot be identified (Hejna et al, 2000; Comella et al, 2001;
Sobrero et al, 2001; Scheithauer et al, 2002).
In conclusion, infusional 5-fluorouracil plus folinic acid
combined with 10mgm
 2 bolus MMC is a safe and well-tolerated
regimen that can be given on an outpatient basis. Toxicity was
generally mild and treatment was well tolerated. Despite other
reports, we did not observe adverse events such as a haemolytic
uraemic syndrome, severe pulmonary toxicity, nephrotoxicity or
microangiopathic haemolytic anaemia The median dose of MMC
applied was 34.7mgm
 2 ranging from 17.5 to 61.8mgm
 2. Thus, a
Table 4 Response to infusional 5-FU/folinic acid plus MMC depending
on the progression-free interval during prior chemotherapy
Response to
MMC/FU/FS
PD during
pretreatment PD after PFI N.e. Total
PR/NC  /2 5/  1/  8
PD 3 1 — 4
Total 5 6 1 12
w
2, P¼0.02. MMC¼mitomycin C; FU¼5-fluorouracil; FS¼folinic acid; PR¼partial
remission; NC¼no change; PD¼progressive disease; PFI¼progression-free interval
; n.e.¼not evaluable.
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lrelationship between the cumulative dose of MMC applied and the
risk of developing haemolytic uraemic syndrome remains unclear
(Becker et al, 1997). However, all patients in the present trial
prophylactically received 50mg prednisolone prior to MMC
(Hartmann et al, 1998a, 1999, 2000). Treatment delays were
mainly due to cumulative thrombocytopenia. While no substantial
efficacy was seen in pretreated patients with colorectal cancer, this
regimen possess clear antitumour activity in patients with
pretreated gastric cancer, particularly in patients with temporary
disease stabilisation after completion of preceding chemotherapy.
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